Ocular Therapeutix (OCUL) Financials

$7.30 -0.30 (-3.95%)

Closing price 04:00 PM Eastern

Extended Trading

$7.30 +0.00 (+0.07%)

As of 05:41 PM Eastern

Annual Income Statements for Ocular Therapeutix

This table shows Ocular Therapeutix's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	-194	-81	-71	-6.55	-156	-86	-60	-63	-45	-40	-29
Consolidated Net Income / (Loss)	-194	-81	-71	-6.55	-156	-86	-60	-63	-45	-40	-29
Net Income / (Loss) Continuing Operations	-194	-81	-71	-6.55	-156	-87	-60	-63	-45	-40	-29
Total Pre-Tax Income	-194	-81	-71	-6.55	-156	-86	-60	-63	-45	-40	-29
Total Operating Income	-172	-82	-79	-78	-63	-86	-59	-62	-43	-38	-27
Total Gross Profit	58	53	47	39	15	1.90	1.53	1.47	1.44	1.43	0.68
Total Revenue	64	58	51	44	17	4.23	1.99	1.92	1.89	1.75	0.77
Operating Revenue	64	58	51	44	17	4.23	1.99	1.92	1.89	1.75	0.77
Total Cost of Revenue	5.63	5.28	4.54	4.41	2.08	2.33	0.47	0.46	0.44	0.32	0.09
Operating Cost of Revenue	5.63	5.28	4.54	4.41	2.08	2.33	0.47	0.46	0.44	0.32	0.09
Total Operating Expenses	230	136	126	117	78	88	61	63	45	40	28
Selling, General & Admin Expense	61	34	32	32	23	22	19	16	11	9.17	6.91
Marketing Expense	42	41	40	35	27	24	4.94	17	6.70	3.85	1.98
Research & Development Expense	128	61	53	50	29	41	37	31	27	27	19
Other Operating Expenses / (Income)	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-
Total Other Income / (Expense), net	-22	1.65	7.62	71	-93	-0.57	-0.86	-1.46	-1.38	-1.55	-1.55
Interest Expense	42	-2.85	7.02	6.67	6.77	6.10	1.74	1.89	1.68	1.72	1.12
Interest & Investment Income	20	3.98	0.80	0.03	0.17	1.23	0.88	0.42	0.30	0.17	0.01
Other Income / (Expense), net	-0.48	-5.19	14	78	-86	4.30	-	0.01	-0.00	0.01	-0.44
Other Gains / (Losses), net	0.00	-0.00	-0.00	-	-	-0.57	-	-	-	-	-
Basic Earnings per Share	($1.22)	($1.01)	($0.92)	($0.09)	($2.56)	($1.91)	($1.57)	($2.20)	($1.80)	($1.71)	($2.69)
Weighted Average Basic Shares Outstanding	158.27M	79.83M	76.88M	76.39M	60.75M	45.27M	38.12M	28.82M	24.82M	23.24M	10.65M
Diluted Earnings per Share	($1.22)	($1.02)	($0.97)	($0.98)	($2.56)	($1.91)	($1.57)	($2.20)	($1.80)	($1.71)	($2.69)
Weighted Average Diluted Shares Outstanding	158.27M	85.60M	82.64M	82.16M	60.75M	45.27M	38.12M	28.82M	24.82M	23.24M	10.65M
Weighted Average Basic & Diluted Shares Outstanding	159.02M	148.63M	77.51M	76.75M	60.75M	45.27M	38.12M	28.82M	24.82M	23.24M	10.65M

This table shows Ocular Therapeutix's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-64	-48	-36	-44	-65	-29	-0.52	-21	-30	-16	-24
Consolidated Net Income / (Loss)	-64	-48	-36	-44	-65	-29	-0.52	-21	-30	-16	-24
Net Income / (Loss) Continuing Operations	-64	-48	-36	-44	-65	-29	-0.52	-21	-30	-16	-24
Total Pre-Tax Income	-64	-48	-36	-44	-65	-29	-0.52	-21	-30	-16	-24
Total Operating Income	-64	-51	-46	-44	-32	-20	-19	-21	-23	-19	-22
Total Gross Profit	9.44	16	14	15	13	13	14	14	12	13	11
Total Revenue	11	17	15	16	15	15	15	15	13	14	12
Operating Revenue	11	17	15	16	15	15	15	15	13	14	12
Total Cost of Revenue	1.26	1.23	1.56	1.51	1.33	1.39	1.38	1.30	1.21	1.01	1.07
Operating Cost of Revenue	1.26	1.23	1.56	1.51	1.33	1.39	1.38	1.30	1.21	1.01	1.07
Total Operating Expenses	73	66	60	59	45	33	33	34	35	32	32
Selling, General & Admin Expense	16	15	12	20	14	8.02	8.58	8.21	9.13	8.35	8.53
Marketing Expense	14	11	11	9.99	10	9.25	9.32	11	11	11	10
Research & Development Expense	43	41	37	29	21	16	15	15	15	14	14
Total Other Income / (Expense), net	-0.14	2.19	9.51	-0.19	-33	-9.17	19	-0.11	-7.77	3.82	-2.64
Interest Expense	2.98	3.11	3.22	3.20	32	4.15	-11	1.99	1.77	1.85	1.80
Interest & Investment Income	3.83	4.67	5.65	6.04	3.92	1.46	1.21	0.75	0.56	0.42	0.29
Other Income / (Expense), net	-0.98	0.62	7.08	-3.03	-5.15	-6.48	6.72	1.13	-6.56	5.24	-1.13
Other Gains / (Losses), net	-0.14	-	-	-0.19	-	-	-	-0.11	-	-	-
Basic Earnings per Share	($0.38)	($0.25)	($0.22)	($0.26)	($0.49)	($0.35)	($0.01)	($0.26)	($0.39)	($0.21)	($0.31)
Weighted Average Basic Shares Outstanding	169.40M	158.27M	166.99M	165.82M	132.02M	79.83M	79.37M	78.05M	77.39M	76.88M	76.98M
Diluted Earnings per Share	($0.38)	($0.25)	($0.22)	($0.26)	($0.49)	($0.12)	($0.25)	($0.26)	($0.39)	($0.19)	($0.31)
Weighted Average Diluted Shares Outstanding	169.40M	158.27M	166.99M	165.82M	132.02M	85.60M	85.14M	78.05M	77.39M	82.64M	76.98M
Weighted Average Basic & Diluted Shares Outstanding	159.30M	159.02M	157.22M	155.92M	154.89M	148.63M	79.42M	79.38M	77.52M	77.51M	77.01M

This table details how cash moves in and out of Ocular Therapeutix's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	196	94	-62	-64	174	-4.48	137	135	3.65	-6.61	20
Net Cash From Operating Activities	-135	-70	-60	-66	-54	-78	-49	-50	-34	-34	-20
Net Cash From Continuing Operating Activities	-135	-70	-60	-66	-54	-78	71	76	-34	-34	-20
Net Income / (Loss) Continuing Operations	-194	-81	-71	-6.55	-156	-86	60	63	-45	-40	-29
Consolidated Net Income / (Loss)	-194	-81	-71	-6.55	-156	-86	-60	-63	-45	-40	-29
Depreciation Expense	3.79	2.98	2.11	2.42	2.77	2.53	2.29	1.63	0.88	0.75	0.55
Amortization Expense	3.73	6.11	4.85	4.63	4.42	3.68	0.40	0.43	0.56	0.45	0.13
Non-Cash Adjustments To Reconcile Net Income	62	10	-0.05	-62	93	4.35	7.48	7.31	7.19	4.30	5.32
Changes in Operating Assets and Liabilities, net	-11	-8.98	4.52	-3.88	1.49	-1.76	0.59	3.55	2.08	0.50	2.16
Net Cash From Investing Activities	-1.29	-6.09	-3.72	-1.19	-0.84	-2.24	-1.89	27	37	-39	-39
Net Cash From Continuing Investing Activities	-1.29	-6.09	-3.72	-1.19	-0.84	-2.24	-1.89	27	37	-39	-39
Purchase of Property, Plant & Equipment	-1.29	-6.09	-3.72	-1.19	-0.84	-2.24	-1.89	-8.25	-1.92	-1.78	-1.26
Net Cash From Financing Activities	332	170	1.45	2.85	228	75	69	32	0.59	66	79
Net Cash From Continuing Financing Activities	332	170	1.45	2.85	228	75	69	32	0.59	66	79
Repayment of Debt	0.00	-31	0.00	-4.17	-3.20	0.00	-5.66	-1.89	-0.52	-2.26	-2.51
Issuance of Debt	0.00	82	0.00	3.72	0.00	37	12	3.70	0.00	1.90	15
Issuance of Common Equity	317	118	0.94	0.99	225	38	62	30	0.91	66	70
Other Financing Activities, net	15	0.55	0.51	2.59	5.79	0.08	0.40	0.69	0.20	0.21	0.04
Cash Interest Paid	22	5.46	2.15	1.93	2.35	2.30	1.52	1.46	1.30	1.25	0.84

This table details how cash moves in and out of Ocular Therapeutix's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-42	-35	-32	-23	287	85	44	-12	-23	-19	-14
Net Cash From Operating Activities	-45	-39	-37	-25	-34	-22	-7.73	-20	-20	-17	-13
Net Cash From Continuing Operating Activities	-45	-39	-37	-25	-34	-22	-7.73	-20	-20	-17	-13
Net Income / (Loss) Continuing Operations	-64	-48	-36	-44	-65	-29	-0.52	-21	-30	-16	-24
Consolidated Net Income / (Loss)	-64	-48	-36	-44	-65	-29	-0.52	-21	-30	-16	-24
Depreciation Expense	0.98	0.95	0.96	0.96	0.92	0.96	0.89	0.65	0.48	0.49	0.51
Amortization Expense	1.44	0.58	0.62	0.57	1.97	1.55	2.07	1.25	1.23	1.24	1.23
Non-Cash Adjustments To Reconcile Net Income	12	6.30	0.58	14	41	12	-17	3.66	12	-4.18	5.59
Changes in Operating Assets and Liabilities, net	5.41	1.13	-2.23	3.27	-13	-8.10	6.99	-4.95	-2.92	1.04	3.70
Net Cash From Investing Activities	-1.93	-0.20	-0.09	-0.74	-0.26	-0.46	-0.26	-1.99	-3.38	-2.15	-0.79
Net Cash From Continuing Investing Activities	-1.93	-0.20	-0.09	-0.74	-0.26	-0.46	-0.26	-1.99	-3.38	-2.15	-0.79
Purchase of Property, Plant & Equipment	-1.93	-0.20	-0.09	-0.74	-0.26	-0.46	-0.26	-1.99	-3.38	-2.15	-0.79
Net Cash From Financing Activities	4.18	4.51	4.18	2.20	321	108	52	9.65	0.08	0.46	0.37
Net Cash From Continuing Financing Activities	4.18	4.51	4.18	2.20	321	108	52	9.65	0.08	0.46	0.37
Issuance of Common Equity	0.00	0.52	-	0.49	316	108	0.71	9.24	0.00	0.46	-
Other Financing Activities, net	4.18	3.99	4.18	1.70	4.87	0.01	0.06	0.40	0.08	-	0.37
Cash Interest Paid	2.14	3.34	2.60	2.63	13	2.60	1.34	0.82	0.70	0.63	0.53

This table presents Ocular Therapeutix's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	458	252	149	205	262	79	73	55	75	110	78
Total Current Assets	441	232	130	191	246	60	56	43	70	107	76
Cash & Equivalents	392	196	102	164	228	54	54	42	33	31	37
Restricted Cash	0.00	0.15	0.00	-	-	-	-	-	-	-	-
Accounts Receivable	32	26	21	21	12	2.55	0.20	0.23	0.25	0.19	0.33
Inventories, net	3.04	2.31	1.97	1.25	1.20	0.95	0.22	0.12	0.11	0.13	0.13
Prepaid Expenses	13	7.79	4.03	4.75	4.65	2.23	1.71	1.45	1.39	1.59	0.89
Plant, Property, & Equipment, net	9.39	12	9.86	6.96	8.10	10	10	10	3.31	3.10	1.78
Total Noncurrent Assets	7.56	8.09	9.81	6.63	7.61	8.42	6.61	1.61	1.73	0.23	0.23
Other Noncurrent Operating Assets	7.56	8.09	8.04	4.87	5.84	6.66	-	-	-	-	-
Total Liabilities & Shareholders' Equity	458	252	149	205	262	79	73	55	75	110	78
Total Liabilities	143	161	114	117	186	82	37	29	23	21	19
Total Current Liabilities	41	35	31	26	27	12	9.16	13	8.30	5.38	5.87
Accounts Payable	4.18	4.39	5.12	4.59	2.71	3.27	2.97	3.57	2.12	1.96	1.32
Accrued Expenses	35	29	24	20	14	7.64	6.19	4.31	4.64	3.38	3.02
Current Deferred Revenue	0.13	0.26	0.58	0.00	-	-	-	-	-	0.04	0.19
Other Current Liabilities	1.93	1.59	1.60	1.62	1.36	1.13	-	-	-	-	-
Total Noncurrent Liabilities	101	126	83	91	159	70	28	16	15	15	14
Long-Term Debt	69	75	54	51	41	49	25	12	14	15	14
Noncurrent Deferred Revenue	14	14	13	13	12	0.00	-	3.39	0.54	0.07	0.11
Other Noncurrent Operating Liabilities	19	37	15	26	106	21	3.22	-	-	-	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	315	91	35	88	76	-3.63	36	26	52	90	59
Total Preferred & Common Equity	315	91	35	88	76	-3.63	36	26	52	90	59
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	315	91	35	88	76	-3.63	36	26	52	90	59
Common Stock	1,206	789	652	634	615	380	333	263	226	219	148
Retained Earnings	-891	-698	-617	-546	-539	-384	-297	-237	-174	-129	-89

This table presents Ocular Therapeutix's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	406	490	517	539	162	123	129	159
Total Current Assets	388	473	499	520	141	101	107	146
Cash & Equivalents	350	427	460	483	111	67	79	121
Accounts Receivable	25	30	30	27	24	27	21	20
Inventories, net	3.27	2.41	2.55	2.57	2.26	2.20	2.27	1.55
Prepaid Expenses	9.52	13	6.12	7.67	4.86	4.59	4.75	3.32
Plant, Property, & Equipment, net	11	10	11	11	12	13	12	7.20
Total Noncurrent Assets	7.44	7.31	7.62	7.67	8.63	9.02	9.39	5.77
Other Noncurrent Operating Assets	7.44	7.31	7.62	7.67	6.87	7.25	7.63	4.00
Total Liabilities & Shareholders' Equity	406	490	517	539	162	123	129	159
Total Liabilities	140	138	139	131	155	119	119	112
Total Current Liabilities	38	36	30	24	35	32	30	29
Accounts Payable	4.63	4.00	3.69	6.45	3.98	3.57	5.44	5.31
Accrued Expenses	31	30	24	16	29	25	22	22
Current Deferred Revenue	0.06	0.19	0.27	0.26	0.32	0.39	0.46	0.60
Other Current Liabilities	2.16	1.72	1.66	1.54	1.88	1.71	1.82	1.74
Total Noncurrent Liabilities	102	102	109	107	119	87	89	83
Long-Term Debt	69	68	67	66	74	53	55	53
Noncurrent Deferred Revenue	14	14	14	14	14	14	13	14
Other Noncurrent Operating Liabilities	19	20	28	26	31	20	21	16
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	266	352	378	408	7.85	3.09	9.71	46
Total Preferred & Common Equity	266	352	378	408	7.85	3.09	9.71	46
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	266	352	378	408	7.85	3.09	9.71	46
Common Stock	1,221	1,195	1,184	1,170	676	671	657	648
Retained Earnings	-955	-843	-806	-762	-668	-668	-647	-601

This table displays calculated financial ratios and metrics derived from Ocular Therapeutix's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	9.03%	13.49%	18.32%	150.08%	311.71%	112.41%	3.48%	1.91%	7.83%	126.68%	0.00%
EBITDA Growth	-109.91%	-35.66%	-910.92%	105.03%	-88.41%	-33.40%	5.73%	-42.92%	-13.25%	-37.69%	-115.95%
EBIT Growth	-96.71%	-35.11%	-76,350.59%	100.06%	-82.87%	-37.86%	4.52%	-42.91%	-13.45%	-38.69%	-113.64%
NOPAT Growth	-108.52%	-4.74%	-0.79%	-24.17%	26.75%	-45.14%	4.53%	-42.92%	-13.43%	-40.98%	-109.98%
Net Income Growth	-139.68%	-13.65%	-984.05%	95.79%	-80.19%	-44.01%	5.38%	-41.79%	-12.47%	-38.75%	-115.12%
EPS Growth	-19.61%	-5.15%	1.02%	61.72%	-34.03%	-21.66%	28.64%	-22.22%	-5.26%	36.43%	47.36%
Operating Cash Flow Growth	-91.75%	-17.84%	9.07%	-22.40%	30.97%	-57.59%	2.47%	-48.45%	-0.76%	-64.63%	-62.09%
Free Cash Flow Firm Growth	-234.30%	36.53%	49.46%	-366.35%	200.25%	-22.79%	13.35%	-63.22%	-2.65%	-55.53%	-107.17%
Invested Capital Growth	72.40%	-103.70%	44.60%	74.57%	-890.52%	-80,815.38%	-101.29%	145.50%	-414.35%	71.10%	-270.05%
Revenue Q/Q Growth	3.71%	1.26%	3.55%	12.86%	41.37%	70.79%	-17.46%	27.44%	4.14%	-3.79%	0.00%
EBITDA Q/Q Growth	-17.39%	-17.39%	-26.09%	109.57%	-72.36%	1.77%	-8.62%	-0.24%	-6.05%	-6.39%	0.00%
EBIT Q/Q Growth	-15.74%	-16.51%	-22.58%	100.10%	-66.39%	0.23%	-8.37%	-0.39%	-5.34%	-7.67%	0.00%
NOPAT Q/Q Growth	-21.61%	-0.84%	-1.70%	-4.99%	10.10%	-5.04%	-8.37%	-0.40%	-5.34%	-7.69%	0.00%
Net Income Q/Q Growth	-10.99%	-20.40%	-19.70%	92.58%	-62.05%	-11.08%	-7.72%	-0.44%	-5.14%	-7.24%	0.00%
EPS Q/Q Growth	-11.93%	6.42%	6.73%	51.49%	-50.59%	-1.06%	1.26%	3.08%	-4.05%	-259.81%	0.00%
Operating Cash Flow Q/Q Growth	-14.42%	-8.49%	-3.12%	-15.72%	19.80%	-8.11%	-7.10%	-5.81%	2.92%	-9.79%	-11.84%
Free Cash Flow Firm Q/Q Growth	-16.24%	14.69%	9.49%	-260.47%	270.42%	-2.83%	-4.97%	-6.46%	1.90%	0.00%	0.00%
Invested Capital Q/Q Growth	-11.77%	2.19%	36.57%	38.22%	-278.06%	-35.22%	-101.08%	6.87%	-702.17%	-726.09%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	91.17%	90.96%	91.18%	89.88%	88.03%	45.00%	76.63%	76.24%	76.52%	81.77%	88.21%
EBITDA Margin	-258.53%	-134.29%	-112.35%	16.39%	-815.08%	-1,781.10%	-2,835.93%	-3,113.26%	-2,219.87%	-2,113.54%	-3,479.53%
Operating Margin	-269.57%	-140.96%	-152.74%	-179.30%	-361.13%	-2,029.86%	-2,970.75%	-3,220.12%	-2,296.03%	-2,182.69%	-3,509.59%
EBIT Margin	-270.33%	-149.84%	-125.87%	0.20%	-856.38%	-1,928.08%	-2,970.75%	-3,219.86%	-2,296.08%	-2,182.29%	-3,566.84%
Profit (Net Income) Margin	-303.67%	-138.14%	-137.95%	-15.06%	-894.31%	-2,043.34%	-3,013.97%	-3,296.20%	-2,369.00%	-2,271.31%	-3,710.88%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	112.33%	92.19%	109.60%	-7,709.41%	104.43%	105.98%	101.45%	102.37%	103.18%	104.08%	104.04%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-8,293.11%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-8,232.16%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8,099.70%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-95.21%	-127.64%	-115.16%	-7.99%	-429.55%	-535.72%	-193.41%	-162.21%	-63.14%	-53.61%	-77.88%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4,607.23%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-48.52%	-43.64%	-36.60%	0.04%	-87.51%	-107.39%	-92.03%	-94.99%	-46.78%	-40.52%	-56.58%
Return on Assets (ROA)	-54.51%	-40.23%	-40.11%	-2.81%	-91.39%	-113.81%	-93.37%	-97.24%	-48.26%	-42.17%	-58.86%
Return on Common Equity (ROCE)	-95.21%	-127.64%	-115.16%	-7.99%	-429.55%	-535.72%	-193.41%	-162.21%	-63.14%	-53.61%	0.82%
Return on Equity Simple (ROE_SIMPLE)	-61.36%	-88.59%	-200.79%	-7.45%	-204.53%	2,379.39%	-167.19%	-242.42%	-85.95%	-44.37%	-48.81%
Net Operating Profit after Tax (NOPAT)	-120	-58	-55	-55	-44	-60	-41	-43	-30	-27	-19
NOPAT Margin	-188.70%	-98.67%	-106.92%	-125.51%	-252.79%	-1,420.90%	-2,079.53%	-2,254.09%	-1,607.22%	-1,527.88%	-2,456.71%
Net Nonoperating Expense Percent (NNEP)	-32.95%	-26.97%	-19.42%	32.62%	-119.29%	-123.01%	-60.94%	-50.50%	-19.93%	-17.32%	-25.66%
Return On Investment Capital (ROIC_SIMPLE)	-31.33%	-34.73%	-61.60%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	8.83%	9.04%	8.82%	10.12%	11.97%	55.00%	23.37%	23.77%	23.48%	18.23%	11.79%
SG&A Expenses to Revenue	95.18%	58.07%	62.58%	73.25%	131.35%	523.35%	944.02%	806.50%	583.15%	523.71%	895.47%
R&D to Revenue	200.30%	104.47%	103.82%	115.08%	164.88%	972.11%	1,855.03%	1,605.82%	1,434.29%	1,520.63%	2,445.60%
Operating Expenses to Revenue	360.75%	231.93%	243.93%	269.18%	449.16%	2,074.85%	3,047.39%	3,296.36%	2,372.55%	2,264.46%	3,597.80%
Earnings before Interest and Taxes (EBIT)	-172	-88	-65	0.09	-149	-82	-59	-62	-43	-38	-28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-165	-78	-58	7.13	-142	-75	-56	-60	-42	-37	-27
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.26	3.89	6.12	6.07	19.42	0.00	4.56	5.01	4.00	2.59	8.54
Price to Tangible Book Value (P/TBV)	4.26	3.89	6.12	6.07	19.42	0.00	4.56	5.01	4.00	2.59	8.54
Price to Revenue (P/Rev)	21.07	6.06	4.20	12.27	84.92	44.93	82.19	68.12	110.36	132.43	649.62
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	106.31	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	15.99	3.99	3.26	9.68	74.66	43.72	67.48	55.89	82.53	81.12	571.94
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	59.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	4,955.81	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	26.15	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.22	0.82	1.53	0.58	0.65	-13.58	0.69	0.69	0.30	0.17	0.25
Long-Term Debt to Equity	0.22	0.82	1.53	0.58	0.54	-13.58	0.69	0.48	0.27	0.17	0.23
Financial Leverage	-1.09	-1.35	-1.33	-1.80	-2.58	-1.33	-0.98	-1.02	-1.02	-1.01	-1.03
Leverage Ratio	1.75	3.17	2.87	2.84	4.70	4.71	2.07	1.67	1.31	1.27	1.32
Compound Leverage Factor	1.96	2.92	3.15	-219.29	4.91	4.99	2.10	1.71	1.35	1.32	1.38
Debt to Total Capital	17.85%	45.12%	60.42%	36.89%	39.43%	107.95%	40.86%	40.79%	23.12%	14.56%	20.21%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	6.60%	0.00%	0.00%	12.56%	2.29%	0.00%	1.84%
Long-Term Debt to Total Capital	17.85%	45.12%	60.42%	36.89%	32.83%	107.95%	40.86%	28.24%	20.83%	14.56%	18.37%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	82.15%	54.88%	39.58%	63.11%	60.57%	-7.95%	59.14%	59.21%	76.88%	85.44%	79.79%
Debt to EBITDA	-0.42	-0.95	-0.93	7.21	-0.35	-0.66	-0.44	-0.30	-0.37	-0.41	-0.55
Net Debt to EBITDA	1.96	1.54	0.83	-15.80	1.26	0.07	0.52	0.39	1.25	2.43	2.23
Long-Term Debt to EBITDA	-0.42	-0.95	-0.93	7.21	-0.29	-0.66	-0.44	-0.21	-0.34	-0.41	-0.50
Debt to NOPAT	-0.57	-1.30	-0.98	-0.94	-1.13	-0.82	-0.60	-0.42	-0.52	-0.57	-0.78
Net Debt to NOPAT	2.69	2.10	0.88	2.06	4.06	0.09	0.71	0.54	1.73	3.36	3.16
Long-Term Debt to NOPAT	-0.57	-1.30	-0.98	-0.94	-0.94	-0.82	-0.60	-0.29	-0.46	-0.57	-0.71
Altman Z-Score	2.87	-2.53	-4.94	0.19	1.08	-8.07	-4.93	-6.31	1.30	5.05	13.76
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	101.05%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.66	6.66	4.13	7.26	9.23	5.00	6.14	3.23	8.42	19.89	12.97
Quick Ratio	10.26	6.36	3.94	7.04	9.01	4.74	5.92	3.11	8.24	19.57	12.79
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-142	-42	-67	-132	50	-50	-40	-47	-29	-28	-18
Operating Cash Flow to CapEx	-10,456.29%	-1,153.84%	-1,604.39%	-5,489.95%	-6,367.90%	-3,466.40%	-2,605.98%	-612.02%	-1,773.66%	-1,905.31%	-1,626.67%
Free Cash Flow to Firm to Interest Expense	-3.42	0.00	-9.52	-19.84	7.34	-8.12	-23.21	-24.62	-16.99	-16.13	-15.97
Operating Cash Flow to Interest Expense	-3.24	0.00	-8.49	-9.83	-7.91	-12.72	-28.31	-26.68	-20.24	-19.57	-18.32
Operating Cash Flow Less CapEx to Interest Expense	-3.27	0.00	-9.02	-10.01	-8.04	-13.08	-29.39	-31.04	-21.38	-20.60	-19.44
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.18	0.29	0.29	0.19	0.10	0.06	0.03	0.03	0.02	0.02	0.02
Accounts Receivable Turnover	2.18	2.46	2.43	2.61	2.35	3.08	9.32	8.08	8.52	6.71	2.58
Inventory Turnover	2.11	2.47	2.82	3.60	1.93	3.97	2.74	3.89	3.59	2.39	0.00
Fixed Asset Turnover	6.03	5.41	6.13	5.78	1.91	0.41	0.19	0.28	0.59	0.72	0.57
Accounts Payable Turnover	1.31	1.11	0.93	1.21	0.70	0.75	0.14	0.16	0.22	0.19	0.10
Days Sales Outstanding (DSO)	167.73	148.34	150.48	140.00	155.20	118.69	39.16	45.17	42.84	54.44	141.37
Days Inventory Outstanding (DIO)	173.38	147.87	129.60	101.52	188.81	91.92	133.05	93.85	101.76	152.75	0.00
Days Payable Outstanding (DPO)	277.84	328.71	390.53	302.41	523.67	489.26	2,565.20	2,271.07	1,677.93	1,872.48	3,732.23
Cash Conversion Cycle (CCC)	63.28	-32.50	-110.44	-60.89	-179.66	-278.65	-2,393.00	-2,132.05	-1,533.33	-1,665.30	-3,590.86
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-8.25	-30	-15	-26	-104	-11	-0.01	1.01	-2.22	-0.43	-1.50
Invested Capital Turnover	-3.34	-2.62	-2.50	-0.67	-0.30	-0.80	3.99	-3.18	-1.42	-1.82	-0.81
Increase / (Decrease) in Invested Capital	22	-15	12	78	-94	-11	-1.02	3.23	-1.79	1.06	-1.09
Enterprise Value (EV)	1,019	233	168	421	1,299	185	134	107	156	142	442
Market Capitalization	1,343	354	216	534	1,478	190	164	131	208	232	502
Book Value per Share	$2.01	$1.15	$0.46	$1.15	$1.07	($0.08)	$0.87	$0.89	$2.09	$3.62	$2.75
Tangible Book Value per Share	$2.01	$1.15	$0.46	$1.15	$1.07	($0.08)	$0.87	$0.89	$2.09	$3.62	$2.75
Total Capital	384	166	89	139	126	46	61	44	68	105	74
Total Debt	69	75	54	51	50	49	25	18	16	15	15
Total Long-Term Debt	69	75	54	51	41	49	25	12	14	15	14
Net Debt	-324	-121	-48	-113	-179	-5.13	-29	-24	-53	-90	-60
Capital Expenditures (CapEx)	1.29	6.09	3.72	1.19	0.84	2.24	1.89	8.25	1.92	1.77	1.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)	7.53	1.38	-4.07	0.80	-0.27	-6.30	-7.03	-6.08	-5.00	-3.46	-3.17
Debt-free Net Working Capital (DFNWC)	400	197	98	165	228	48	47	35	63	102	72
Net Working Capital (NWC)	400	197	98	165	219	48	47	30	62	102	70
Net Nonoperating Expense (NNE)	73	23	16	-48	112	26	19	20	14	13	9.68
Net Nonoperating Obligations (NNO)	-324	-121	-50	-114	-180	-6.89	-36	-25	-54	-90	-60
Total Depreciation and Amortization (D&A)	7.52	9.09	6.96	7.05	7.19	6.21	2.68	2.05	1.44	1.20	0.67
Debt-free, Cash-free Net Working Capital to Revenue	11.82%	2.36%	-7.90%	1.84%	-1.56%	-148.95%	-353.17%	-316.17%	-264.86%	-197.66%	-409.97%
Debt-free Net Working Capital to Revenue	627.14%	337.66%	190.76%	379.03%	1,308.89%	1,138.89%	2,363.52%	1,843.89%	3,346.42%	5,806.00%	9,282.77%
Net Working Capital to Revenue	627.14%	337.66%	190.76%	379.03%	1,261.25%	1,138.89%	2,363.52%	1,555.54%	3,264.33%	5,806.00%	9,107.38%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.22)	($1.01)	($0.92)	($0.09)	($2.56)	($1.91)	($1.57)	($2.20)	($1.80)	($1.71)	($2.69)
Adjusted Weighted Average Basic Shares Outstanding	158.27M	79.83M	76.88M	76.39M	76.07M	52.58M	42.84M	37.28M	28.76M	24.75M	21.42M
Adjusted Diluted Earnings per Share	($1.22)	($1.02)	($0.97)	($0.98)	($2.56)	($1.91)	($1.57)	($2.20)	($1.80)	($1.71)	($2.69)
Adjusted Weighted Average Diluted Shares Outstanding	158.27M	85.60M	82.64M	82.16M	76.07M	52.58M	42.84M	37.28M	28.76M	24.75M	21.42M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($2.56)	($1.91)	($1.57)	($2.20)	($1.80)	($1.71)	($2.69)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	159.02M	148.63M	77.51M	76.75M	60.75M	45.27M	38.12M	28.82M	24.82M	23.24M	10.65M
Normalized Net Operating Profit after Tax (NOPAT)	-120	-58	-55	-55	-44	-60	-41	-43	-30	-27	-19
Normalized NOPAT Margin	-188.70%	-98.67%	-106.92%	-125.51%	-252.79%	-1,420.90%	-2,079.53%	-2,254.09%	-1,607.22%	-1,527.88%	-2,456.71%
Pre Tax Income Margin	-303.67%	-138.14%	-137.95%	-15.06%	-894.31%	-2,043.34%	-3,013.97%	-3,296.20%	-2,369.00%	-2,271.31%	-3,710.88%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-4.15	0.00	-9.23	0.01	-22.02	-13.36	-34.00	-32.73	-25.79	-22.15	-24.61
NOPAT to Interest Expense	-2.90	0.00	-7.84	-8.19	-6.50	-9.84	-23.80	-22.91	-18.05	-15.51	-16.95
EBIT Less CapEx to Interest Expense	-4.18	0.00	-9.76	-0.17	-22.14	-13.73	-35.08	-37.09	-26.93	-23.18	-25.73
NOPAT Less CapEx to Interest Expense	-2.93	0.00	-8.37	-8.37	-6.62	-10.21	-24.88	-27.27	-19.19	-16.54	-18.07
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-4.20%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-10.53%

This table displays calculated financial ratios and metrics derived from Ocular Therapeutix's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-27.59%	15.41%	2.28%	8.26%	10.47%	5.16%	26.04%	23.81%	1.42%	14.36%	-1.55%
EBITDA Growth	-84.40%	-101.65%	-291.84%	-157.17%	-23.64%	-93.84%	54.49%	-13.96%	-200.00%	-2,856.80%	-445.58%
EBIT Growth	-76.49%	-88.32%	-211.58%	-139.81%	-26.30%	-87.90%	44.91%	-13.39%	-167.66%	-548.46%	-626.37%
NOPAT Growth	-102.16%	-152.26%	-139.40%	-111.91%	-40.21%	-3.55%	10.82%	-3.28%	-26.45%	-7.27%	22.78%
Net Income Growth	1.23%	-65.60%	-6,972.29%	-111.67%	-113.89%	-88.01%	97.87%	-10.21%	-141.73%	-303.69%	-1,010.35%
EPS Growth	22.45%	-108.33%	12.00%	0.00%	-25.64%	36.84%	19.35%	-4.00%	-77.27%	26.92%	-34.78%
Operating Cash Flow Growth	-31.82%	-75.60%	-372.83%	-23.55%	-69.66%	-32.41%	41.29%	-84.58%	-7.38%	-11.91%	-1.44%
Free Cash Flow Firm Growth	-29.60%	-4,903.50%	-820.23%	-14.71%	-103.45%	104.68%	82.72%	62.40%	80.86%	71.92%	-727.93%
Invested Capital Growth	-69.19%	72.40%	75.85%	-49.89%	47.57%	-103.70%	-32.11%	44.31%	-6.99%	44.60%	46.04%
Revenue Q/Q Growth	-37.38%	10.75%	-6.18%	11.28%	-0.19%	-1.85%	-0.69%	13.55%	-4.99%	17.64%	-2.45%
EBITDA Q/Q Growth	-29.02%	-29.68%	17.19%	-33.09%	-41.08%	-151.99%	45.65%	36.01%	-121.16%	40.84%	-36.11%
EBIT Q/Q Growth	-29.91%	-28.34%	16.51%	-26.78%	-38.61%	-112.34%	35.74%	33.23%	-106.21%	37.74%	-32.28%
NOPAT Q/Q Growth	-26.38%	-9.95%	-5.52%	-37.87%	-57.70%	-4.35%	6.59%	8.78%	-16.47%	10.13%	-8.17%
Net Income Q/Q Growth	-32.37%	-32.60%	16.64%	32.49%	-121.93%	-5,562.79%	97.51%	31.78%	-95.07%	35.75%	-28.89%
EPS Q/Q Growth	-52.00%	-13.64%	15.38%	46.94%	-308.33%	52.00%	3.85%	33.33%	-105.26%	38.71%	-24.00%
Operating Cash Flow Q/Q Growth	-13.29%	-7.85%	-47.40%	26.81%	-50.92%	-190.40%	61.48%	-0.51%	-17.78%	-28.77%	-21.08%
Free Cash Flow Firm Q/Q Growth	32.01%	-3.01%	-116.64%	14.59%	-2,620.24%	119.73%	73.00%	-51.49%	42.00%	27.15%	41.25%
Invested Capital Q/Q Growth	-76.29%	-11.77%	50.32%	-72.85%	71.24%	2.19%	-208.31%	39.54%	-11.72%	36.57%	-29.97%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	88.20%	92.80%	89.88%	90.82%	91.02%	90.64%	90.87%	91.41%	90.92%	92.81%	91.03%
EBITDA Margin	-584.02%	-283.47%	-242.09%	-274.27%	-229.33%	-162.24%	-63.19%	-115.46%	-204.89%	-88.02%	-175.03%
Operating Margin	-597.47%	-296.06%	-298.20%	-265.13%	-214.00%	-135.45%	-127.41%	-135.45%	-168.60%	-137.55%	-180.06%
EBIT Margin	-606.61%	-292.41%	-252.33%	-283.54%	-248.88%	-179.21%	-82.83%	-128.01%	-217.68%	-100.29%	-189.52%
Profit (Net Income) Margin	-598.74%	-283.25%	-236.58%	-266.27%	-438.93%	-197.41%	-3.42%	-136.19%	-226.69%	-110.41%	-202.16%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.01%	100.00%
Interest Burden Percent	98.70%	96.87%	93.76%	93.91%	176.37%	110.15%	4.13%	106.39%	104.14%	110.09%	106.67%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-57.19%	-95.21%	-96.89%	-72.67%	-55.19%	-127.64%	-247.99%	-263.41%	-198.45%	-115.16%	-88.86%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-76.59%	-52.49%	-47.50%	-54.17%	-44.62%	-52.19%	-29.79%	-47.28%	-71.16%	-29.16%	-50.09%
Return on Assets (ROA)	-75.59%	-50.84%	-44.54%	-50.87%	-78.70%	-57.49%	-1.23%	-50.31%	-74.10%	-32.11%	-53.43%
Return on Common Equity (ROCE)	-57.19%	-95.21%	-96.89%	-72.67%	-55.19%	-127.64%	-247.99%	-263.41%	-198.45%	-115.16%	-88.86%
Return on Equity Simple (ROE_SIMPLE)	-72.47%	0.00%	-49.52%	-36.63%	-28.25%	0.00%	-853.92%	-2,939.10%	-914.57%	0.00%	-128.37%
Net Operating Profit after Tax (NOPAT)	-45	-35	-32	-31	-22	-14	-13	-14	-16	-14	-15
NOPAT Margin	-418.23%	-207.24%	-208.74%	-185.59%	-149.80%	-94.81%	-89.18%	-94.82%	-118.02%	-96.28%	-126.04%
Net Nonoperating Expense Percent (NNEP)	-5.54%	-5.84%	-2.16%	-6.54%	-19.30%	-17.75%	24.00%	-13.01%	-23.98%	-2.42%	-9.13%
Return On Investment Capital (ROIC_SIMPLE)	-13.35%	-9.22%	-	-	-	-8.45%	-	-	-	-15.16%	-
Cost of Revenue to Revenue	11.80%	7.20%	10.12%	9.18%	8.98%	9.36%	9.13%	8.59%	9.08%	7.19%	8.97%
SG&A Expenses to Revenue	152.81%	85.47%	79.32%	119.65%	95.76%	54.21%	56.92%	54.03%	68.24%	59.31%	71.30%
R&D to Revenue	400.61%	239.94%	240.22%	175.52%	140.35%	109.41%	99.59%	99.39%	110.27%	96.21%	114.66%
Operating Expenses to Revenue	685.67%	388.86%	388.08%	355.95%	305.03%	226.08%	218.27%	226.87%	259.53%	230.36%	271.09%
Earnings before Interest and Taxes (EBIT)	-65	-50	-39	-47	-37	-27	-12	-19	-29	-14	-23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-62	-48	-37	-45	-34	-24	-9.53	-18	-27	-12	-21
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.38	4.26	3.85	2.81	3.32	3.89	31.74	129.58	42.06	6.12	6.91
Price to Tangible Book Value (P/TBV)	4.38	4.26	3.85	2.81	3.32	3.89	31.74	129.58	42.06	6.12	6.91
Price to Revenue (P/Rev)	19.54	21.07	22.08	17.34	22.60	6.06	4.32	7.33	7.90	4.20	6.42
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	14.84	15.99	16.23	10.92	15.64	3.99	3.68	7.12	7.43	3.26	5.06
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.26	0.22	0.19	0.18	0.16	0.82	9.41	17.94	5.63	1.53	1.15
Long-Term Debt to Equity	0.26	0.22	0.19	0.18	0.16	0.82	9.41	17.26	5.63	1.53	1.15
Financial Leverage	-1.03	-1.09	-1.11	-1.07	-1.06	-1.35	-1.99	-1.40	-1.35	-1.33	-1.49
Leverage Ratio	1.40	1.75	1.81	1.68	1.60	3.17	5.93	4.29	3.53	2.87	2.82
Compound Leverage Factor	1.38	1.69	1.70	1.58	2.82	3.49	0.25	4.57	3.68	3.16	3.01
Debt to Total Capital	20.65%	17.85%	16.15%	15.09%	14.01%	45.12%	90.39%	94.72%	84.92%	60.42%	53.57%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.56%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	20.65%	17.85%	16.15%	15.09%	14.01%	45.12%	90.39%	91.16%	84.92%	60.42%	53.57%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	79.35%	82.15%	83.85%	84.91%	85.99%	54.88%	9.61%	5.28%	15.08%	39.58%	46.43%
Debt to EBITDA	-0.36	-0.42	-0.48	-0.60	-0.78	-0.95	-1.11	-0.71	-0.72	-0.93	-1.16
Net Debt to EBITDA	1.45	1.96	2.56	3.49	4.90	1.54	0.55	0.14	0.32	0.83	1.47
Long-Term Debt to EBITDA	-0.36	-0.42	-0.48	-0.60	-0.78	-0.95	-1.11	-0.68	-0.72	-0.93	-1.16
Debt to NOPAT	-0.48	-0.57	-0.69	-0.84	-1.04	-1.30	-1.29	-0.94	-0.94	-0.98	-0.99
Net Debt to NOPAT	1.96	2.69	3.63	4.90	6.51	2.10	0.64	0.19	0.42	0.88	1.25
Long-Term Debt to NOPAT	-0.48	-0.57	-0.69	-0.84	-1.04	-1.30	-1.29	-0.91	-0.94	-0.98	-0.99
Altman Z-Score	2.36	3.75	4.41	3.29	5.21	-1.73	-3.91	-5.03	-4.61	-3.82	-2.88
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.22	10.66	13.01	16.64	21.39	6.66	4.03	3.11	3.61	4.13	4.98
Quick Ratio	9.89	10.26	12.58	16.35	20.97	6.36	3.83	2.90	3.37	3.94	4.81
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-39	-57	-55	-26	-30	1.19	-6.02	-22	-15	-25	-35
Operating Cash Flow to CapEx	-2,310.97%	-19,519.31%	-41,077.53%	-3,342.59%	-13,289.02%	-4,891.94%	-2,985.33%	-1,008.79%	-591.09%	-788.74%	-1,658.56%
Free Cash Flow to Firm to Interest Expense	-13.00	-18.37	-17.18	-8.00	-0.94	0.29	0.00	-11.19	-8.32	-13.74	-19.38
Operating Cash Flow to Interest Expense	-14.97	-12.69	-11.34	-7.76	-1.06	-5.41	0.00	-10.08	-11.30	-9.19	-7.33
Operating Cash Flow Less CapEx to Interest Expense	-15.62	-12.76	-11.37	-7.99	-1.07	-5.52	0.00	-11.08	-13.21	-10.35	-7.77
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.13	0.18	0.19	0.19	0.18	0.29	0.36	0.37	0.33	0.29	0.26
Accounts Receivable Turnover	2.30	2.18	2.28	2.12	2.51	2.46	2.66	2.29	2.33	2.43	2.53
Inventory Turnover	1.90	2.11	2.48	2.36	2.23	2.47	2.58	2.49	2.46	2.82	3.35
Fixed Asset Turnover	5.37	6.03	5.45	5.15	5.10	5.41	5.86	5.60	5.55	6.13	7.05
Accounts Payable Turnover	1.00	1.31	1.45	1.54	0.91	1.11	1.06	1.27	1.01	0.93	0.97
Days Sales Outstanding (DSO)	158.39	167.73	159.87	171.88	145.38	148.34	137.20	159.74	156.55	150.48	144.43
Days Inventory Outstanding (DIO)	191.72	173.38	147.15	154.89	163.79	147.87	141.40	146.86	148.49	129.60	108.93
Days Payable Outstanding (DPO)	363.52	277.84	252.03	236.72	402.49	328.71	345.59	288.44	363.07	390.53	376.10
Cash Conversion Cycle (CCC)	-13.41	63.28	54.99	90.05	-93.33	-32.50	-66.98	18.15	-58.04	-110.44	-122.75
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-15	-8.25	-7.38	-15	-8.60	-30	-31	-9.92	-16	-15	-23
Invested Capital Turnover	-5.15	-3.34	-3.24	-4.93	-4.79	-2.62	-2.15	-3.94	-3.26	-2.50	-1.51
Increase / (Decrease) in Invested Capital	-5.95	22	23	-4.95	7.80	-15	-7.43	7.89	-1.07	12	20
Enterprise Value (EV)	885	1,019	997	667	936	233	213	389	384	168	252
Market Capitalization	1,166	1,343	1,357	1,059	1,353	354	249	400	408	216	319
Book Value per Share	$1.67	$2.01	$2.26	$2.44	$2.75	$1.15	$0.10	$0.04	$0.13	$0.46	$0.60
Tangible Book Value per Share	$1.67	$2.01	$2.26	$2.44	$2.75	$1.15	$0.10	$0.04	$0.13	$0.46	$0.60
Total Capital	335	384	420	445	474	166	82	58	64	89	100
Total Debt	69	69	68	67	66	75	74	55	55	54	53
Total Long-Term Debt	69	69	68	67	66	75	74	53	55	54	53
Net Debt	-280	-324	-359	-393	-417	-121	-37	-11	-24	-48	-68
Capital Expenditures (CapEx)	1.93	0.20	0.09	0.74	0.26	0.46	0.26	1.99	3.38	2.15	0.79
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.09	7.53	9.43	8.92	12	1.38	-4.36	3.83	-1.58	-4.07	-4.60
Debt-free Net Working Capital (DFNWC)	350	400	437	469	496	197	106	70	77	98	116
Net Working Capital (NWC)	350	400	437	469	496	197	106	68	77	98	116
Net Nonoperating Expense (NNE)	19	13	4.29	13	43	15	-13	6.28	15	1.99	9.11
Net Nonoperating Obligations (NNO)	-280	-324	-359	-393	-417	-121	-38	-13	-26	-50	-69
Total Depreciation and Amortization (D&A)	2.42	1.53	1.58	1.53	2.89	2.51	2.96	1.91	1.71	1.73	1.73
Debt-free, Cash-free Net Working Capital to Revenue	0.15%	11.82%	15.35%	14.60%	20.87%	2.36%	-7.55%	7.02%	-3.06%	-7.90%	-9.26%
Debt-free Net Working Capital to Revenue	586.40%	627.14%	710.67%	766.99%	828.04%	337.66%	183.99%	129.01%	149.86%	190.76%	233.97%
Net Working Capital to Revenue	586.40%	627.14%	710.67%	766.99%	828.04%	337.66%	183.99%	125.19%	149.86%	190.76%	233.97%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.38)	($0.25)	($0.22)	($0.26)	($0.49)	($0.35)	($0.01)	($0.26)	($0.39)	($0.21)	($0.31)
Adjusted Weighted Average Basic Shares Outstanding	169.40M	158.27M	166.99M	165.82M	132.02M	79.83M	79.37M	78.05M	77.39M	76.88M	76.98M
Adjusted Diluted Earnings per Share	($0.38)	($0.25)	($0.22)	($0.26)	($0.49)	($0.12)	($0.25)	($0.26)	($0.39)	($0.19)	($0.31)
Adjusted Weighted Average Diluted Shares Outstanding	169.40M	158.27M	166.99M	165.82M	132.02M	85.60M	85.14M	78.05M	77.39M	82.64M	76.98M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	159.30M	159.02M	157.22M	155.92M	154.89M	148.63M	79.42M	79.38M	77.52M	77.51M	77.01M
Normalized Net Operating Profit after Tax (NOPAT)	-45	-35	-32	-31	-22	-14	-13	-14	-16	-14	-15
Normalized NOPAT Margin	-418.23%	-207.24%	-208.74%	-185.59%	-149.80%	-94.81%	-89.18%	-94.82%	-118.02%	-96.28%	-126.04%
Pre Tax Income Margin	-598.74%	-283.25%	-236.58%	-266.27%	-438.93%	-197.40%	-3.42%	-136.19%	-226.69%	-110.41%	-202.16%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-21.75	-16.08	-12.07	-14.59	-1.15	-6.39	0.00	-9.76	-16.47	-7.65	-12.62
NOPAT to Interest Expense	-14.99	-11.40	-9.99	-9.55	-0.69	-3.38	0.00	-7.23	-8.93	-7.34	-8.39
EBIT Less CapEx to Interest Expense	-22.40	-16.15	-12.10	-14.82	-1.16	-6.50	0.00	-10.76	-18.38	-8.81	-13.06
NOPAT Less CapEx to Interest Expense	-15.64	-11.46	-10.01	-9.78	-0.70	-3.49	0.00	-8.23	-10.84	-8.51	-8.83
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Ocular Therapeutix's Financials

When does Ocular Therapeutix's fiscal year end?

According to the most recent income statement we have on file, Ocular Therapeutix's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Ocular Therapeutix's net income changed over the last 10 years?

Ocular Therapeutix's net income appears to be on an upward trend, with a most recent value of -$193.51 million in 2024, rising from -$28.65 million in 2014. The previous period was -$80.74 million in 2023. View Ocular Therapeutix's forecast to see where analysts expect Ocular Therapeutix to go next.

What is Ocular Therapeutix's operating income?

Ocular Therapeutix's total operating income in 2024 was -$171.78 million, based on the following breakdown:

Total Gross Profit: $58.10 million
Total Operating Expenses: $229.88 million

How has Ocular Therapeutix revenue changed over the last 10 years?

Over the last 10 years, Ocular Therapeutix's total revenue changed from $772 thousand in 2014 to $63.72 million in 2024, a change of 8,154.3%.

How much debt does Ocular Therapeutix have?

Ocular Therapeutix's total liabilities were at $142.59 million at the end of 2024, a 11.4% decrease from 2023, and a 631.3% increase since 2014.

How much cash does Ocular Therapeutix have?

In the past 10 years, Ocular Therapeutix's cash and equivalents has ranged from $30.78 million in 2015 to $392.10 million in 2024, and is currently $392.10 million as of their latest financial filing in 2024.

How has Ocular Therapeutix's book value per share changed over the last 10 years?

Over the last 10 years, Ocular Therapeutix's book value per share changed from 2.75 in 2014 to 2.01 in 2024, a change of -27.1%.

Related Companies

This page (NASDAQ:OCUL) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ocular Therapeutix (OCUL) Financials

Frequently Asked Questions About Ocular Therapeutix's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ocular Therapeutix (OCUL) Financials

Annual Income Statements for Ocular Therapeutix

Quarterly Income Statements for Ocular Therapeutix

Annual Cash Flow Statements for Ocular Therapeutix

Quarterly Cash Flow Statements for Ocular Therapeutix

Annual Balance Sheets for Ocular Therapeutix

Quarterly Balance Sheets for Ocular Therapeutix

Annual Metrics And Ratios for Ocular Therapeutix

Quarterly Metrics And Ratios for Ocular Therapeutix

Frequently Asked Questions About Ocular Therapeutix's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools